0 546

Cited 16 times in

Cited 0 times in

Empirical Treatment With Carbapenem vs Third-generation Cephalosporin for Treatment of Spontaneous Bacterial Peritonitis

Authors
 Kim, Sun Woong  ;  Yoon, Jun Sik  ;  Park, Junyong  ;  Jung, Yong Jin  ;  Lee, Jae Seung  ;  Song, Jisoo  ;  Lee, Han Ah  ;  Seo, Yeon Seok  ;  Lee, Minjong  ;  Park, Jin Myung  ;  Choi, Dae Hee  ;  Kim, Moon Young  ;  Kang, Seong Hee  ;  Yang, Jin Mo  ;  Song, Do Seon  ;  Chung, Sung Won  ;  Kim, Minseok Albert  ;  Jang, Hee Joon  ;  Oh, Hyunwoo  ;  Lee, Cheol-Hyung  ;  Lee, Yun Bin  ;  Cho, Eun Ju  ;  Yu, Su Jong  ;  Kim, Yoon Jun  ;  Yoon, Jung-Hwan  ;  Lee, Jeong-Hoon 
Citation
 CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, Vol.19(5) : 976-986, 2021-05 
Journal Title
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
ISSN
 1542-3565 
Issue Date
2021-05
Keywords
Cirrhosis ; Ascites ; Risk of Death ; Therapy
Abstract
BACKGROUND & AIMS: Third-generation cephalosporins (TGCs) are recommended as first-line antibiotics for treatment of spontaneous bacterial peritonitis (SBP). However, antibiotics against multidrugresistant organisms (such as carbapenems) might be necessary. We aimed to evaluate whether carbapenems are superior to TGC for treatment of SBP. METHODS: We performed a retrospective study of 865 consecutive patients with a first presentation of SBP (275 culture positive; 103 with TGC-resistant bacterial infections) treated at 7 referral centers in Korea, from September 2013 through January 2018. The primary outcome was in-hospital mortality. We made all comparisons using data from patients whose baseline characteristics were balanced by inverse probability of treatment weighting. RESULTS: Of patients who initially received empirical treatment with antibiotics, 95 (11.0%) received carbapenems and 655 (75.7%) received TGCs. Among the entire study cohort, there was no significant difference in in-hospital mortality between the carbapenem (25.8%) and TGC (25.3%) groups (adjusted odds ratio [aOR], 0.97; 95% CI, 0.85-1.11; P [.66). In the subgroup of patients with high chronic liver failure-sequential organ failure assessment (CLIF-SOFA) scores (score of 7 or greater, n [ 314), carbapenem treatment was associated with lower inhospital mortality (23.1%) than in the TGC group (38.8%) (aOR, 0.84; 95% CI, 0.75-0.94; P[.002). In contrast, among patients with lower CLIF-SOFA scores (n [ 436), in-hospital mortality did not differ significantly between the carbapenem group (24.7%) and the TGC group (16.0%) (aOR, 1.06; 95% CI, 0.85-1.32; P [.58). CONCLUSIONS: For patients with a first presentation of SBP, empirical treatment with carbapenem does not reduce in-hospital mortality compared to treatment with TGCs. However, among critically ill patients (CLIF-SOFA scores Phi 7), empirical carbapenem treatment was significantly associated with lower in-hospital mortality than TGCs.
DOI
10.1016/j.cgh.2020.06.046
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Park, Jun Yong(박준용) ORCID logo https://orcid.org/0000-0001-6324-2224
Lee, Jae Seung(이재승) ORCID logo https://orcid.org/0000-0002-2371-0967
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/182867
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links